Program
BL-M08D1
A development code.
Its studies are mostly in Melanoma · Digestive System Neoplasms · Lymphoma, Large B-Cell, Diffuse · Nasopharyngeal Carcinoma · Squamous Cell Carcinoma of Head and Neck, led by Sichuan Biokin Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Biokin Pharmaceutical | 88 open or running | phase 2since Aug 19, 2026 | Dec 2, 2024 | Dec 2026phase 1 · NCT06718621 |
Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 2, 2024First studies: 2 phase 1 studiesFirst studyNCT06718634, NCT06718621
- Aug 19, 20263 phase 2 studiesPhase 2 reachedNCT07780318, NCT07788950, NCT07793825
- Sep 8, 20263 phase 2 studiesNCT07818499, NCT07818486, NCT07841925
Ahead
- Dec 2026Primary completion: phase 1 study in Solid TumorNCT06718621
- Jun 2027Primary completion: phase 1 study in RecurrenceNCT06718634
- Dec 2028Primary completion: phase 2 study in MelanomaNCT07841925
- Dec 2028Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT07818499
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07841925Melanoma · China | 2 | Recruiting | Dec 2028 | 30 |
| NCT07818499Lymphoma, Large B-Cell, Diffuse · China | 2 | Not yet recruiting | Dec 2028 | 204 |
| NCT07818486Nasopharyngeal Carcinoma · China | 2 | Not yet recruiting | Dec 2028 | 30 |
| NCT07793825Gynecological Tumors · China | 2 | Not yet recruiting | Dec 2028 | 90 |
| NCT07788950Squamous Cell Carcinoma of Head and Neck · China | 2 | Not yet recruiting | Dec 2028 | 30 |
| NCT07780318Digestive System Neoplasms · China | 2 | Recruiting | Dec 2028 | 60 |
| NCT06718634Recurrence · China | 1 | Recruiting | Jun 2027 | 22 |
| NCT06718621Solid Tumor · China | 1 | Recruiting | Dec 2026 | 22 |
How it is read
Names in the registry
- “BL-M08D1”, 8 entries
Codes read as this program: BLM08D1.
Conditions, from the studies’ own filings
- Melanoma, 1 study
- Digestive System Neoplasms, 1 study
- Lymphoma, Large B-Cell, Diffuse, 1 study
- Nasopharyngeal Carcinoma, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.